

*Search*

=> d his

(FILE 'HOME' ENTERED AT 18:03:36 ON 28 OCT 2004)

FILE 'REGISTRY' ENTERED AT 18:03:42 ON 28 OCT 2004

|     |                    |
|-----|--------------------|
| L1  | 1 S NIZATIDINE/CN  |
| L2  | 1 S FAMOTIDINE/CN  |
| L3  | 1 S CIMETIDINE/CN  |
| L4  | 1 S RANITIDINE/CN  |
| L5  | 1 S OLANZAPINE/CN  |
| L6  | 1 S CLOZAPINE/CN   |
| L7  | 1 S RISPERIDONE/CN |
| L8  | 0 S QUETIAPIN/CN   |
| L9  | 1 S QUETIAPINE/CN  |
| L10 | 0 S DIVALPROEX/CN  |
| L11 | 1 S DIVALPROEX     |
| L12 | 1 S MIRTAPAZINE/CN |

FILE 'EMBASE, USPATFULL, CAPLUS, MEDLINE, IPA' ENTERED AT 18:05:17 ON 28 OCT 2004

|         |   |
|---------|---|
| L13     | 62859 S L1 OR L2 OR L3 OR L4 OR (H2 ANTAGONIST#) OR ZANTAC OR   |
| TAGAMET |   |
| L14     | 94740 S L5 OR L6 OR L7 OR L9 OR L11 OR L12 OR (PSYCHOTROPIC#### |
| DRUG#   |   |
| L15     | 254 S 13 (20W) L14  |
| L16     | 7 S L13 (20W) L14   |
| L17     | 6 DUPLICATE REMOVE  |

L17 ANSWER 1 OF 6 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003311229 EMBASE  
TITLE: Current drug use as risk factor for erectile dysfunction:  
Results from an Italian epidemiological study.  
AUTHOR: Ricci E.; Parazzini F.; Mirone V.; Imbimbo C.; Palmieri  
A.;  
CORPORATE SOURCE: Bortolotti A.; Di Cintio E.; Landoni M.; Lavezzari M.  
E. Ricci, Ist. di Ric. Farmacol. 'Mario Negri', via  
Eritrea, Milano 62-20157, Italy. ricci@marionegri.it  
SOURCE: International Journal of Impotence Research, (2003) 15/3  
(221-224).  
Refs: 17  
ISSN: 0955-9930 CODEN: IJIRFB  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology  
028 Urology and Nephrology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English  
SUMMARY LANGUAGE: English

AB . . . 1.4-6.9) and anticholinergic drugs (OR 12.8, 95% CI 2.7-60.1)  
were associated with ED risk. No association emerged between ED and  
**H2 antagonists**, anticholesterolemic or hypoglycemic  
drugs. In conclusion, after taking account of related pathologies, our  
results suggest that men treated with **antipsychotic**, diuretic  
and anticholinergic drugs are at greater risk of ED.

L17 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:45096 CAPLUS  
DOCUMENT NUMBER: 138:180577  
TITLE: Glucose intolerance with atypical antipsychotics  
AUTHOR(S): Hedenmalm, Karin; Hagg, Staffan; Stahl, Malin;  
Mortimer, Orjan; Spigset, Olav  
CORPORATE SOURCE: Drug Epidemiology Unit, Medical Products Agency,  
Uppsala, Swed.  
SOURCE: Drug Safety (2002), 25(15), 1107-1116  
CODEN: DRSAEA; ISSN: 0114-5916  
PUBLISHER: Adis International Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR  
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine  
56-54-2, Quinidine 72-69-5, Nortriptyline 92-84-2D, Phenothiazine,  
derivs. 113-53-1, Dosulepine 261-31-4D, Thioxanthene, derivs.  
303-49-1, Clomipramine 315-72-0 438-60-8, Protriptyline 495-40-9D,  
Butyrophenone, derivs. 1668-19-5, Doxepine 4498-32-2, Dibenzepine  
7439-93-2, Lithium, biological studies 10262-69-8, Maprotiline  
23047-25-8, Lofepramine **51481-61-9**, Cimetidine 57574-09-1,  
Amineptine 93413-69-5, Venlafaxine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(not assocd. with glucose intolerance with atypical

**antipsychotic use; glucose intolerance with atypical antipsychotics vs. conventional antipsychotics for treatment of psychosis patients)**

L17 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:881023 CAPLUS

DOCUMENT NUMBER: 134:33017

TITLE: Combination for treating weight gain associated with antipsychotic use comprising an atypical

antipsychotic

and an H2 antagonist

INVENTOR(S): Todd, Jane Rogers

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2000074784          | A1   | 20001214 | WO 2000-US9811  | 20000522   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| EP 1189662             | A1   | 20020327 | EP 2000-931932  | 20000522   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | US 1999-138315P | P 19990609 |
|                        |  |          | WO 2000-US9811  | W 20000522 |

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT Antihistamines

(H2; atypical antipsychotic and H2 antagonist combination for treating wt. gain assocd. with antipsychotic therapy)

IT Drug delivery systems

(aerosols; atypical antipsychotic and H2 antagonist combination for treating wt. gain assocd. with antipsychotic therapy)

IT Antipsychotics

Body weight

(atypical antipsychotic and H2 antagonist combination for treating wt. gain assocd. with antipsychotic therapy)

IT Drug delivery systems

(capsules; atypical antipsychotic and H2 antagonist combination for treating wt. gain assocd. with antipsychotic

therapy)

IT Drug delivery systems  
(solns., i.v.; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems  
(suppositories; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems  
(suspensions; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems  
(tablets; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT 5786-21-0, Clozapine **51481-61-9**, Cimetidine **66357-35-5**,  
Ranitidine **76824-35-6**, Famotidine **76963-41-2**,  
Nizatidine 106266-06-2, Risperidone 106516-24-9, Sertindole  
111974-69-7, Quetiapine 132539-06-1, Olanzapine 146939-27-7,  
Ziprasidone  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(atypical **antipsychotic** and **H2 antagonist**  
combination for treating wt. gain assocd. with **antipsychotic**  
therapy)

L17 ANSWER 4 OF 6 IPA COPYRIGHT 2004 ASHP on STN

ACCESSION NUMBER: 2001:6772 IPA  
DOCUMENT NUMBER: 38-06772  
TITLE: Drug interactions with cisapride: clinical implications  
AUTHOR: Landrum Michalets, E.; Rhinehart Williams, C.  
CORPORATE SOURCE: Mission + St. Joseph's Dept. of Pharm., 509 Biltmore Ave.,  
Asheville, NC 28801, USA Internet: msj.cphelm@memo.msj.org  
SOURCE: Clinical Pharmacokinetics (New Zealand), (Jul 2000) Vol.  
39, pp. 49-75. 257 Refs.  
CODEN: CPKNDH; ISSN: 0312-5963.  
DOCUMENT TYPE: General Review  
FILE SEGMENT: HUMAN  
LANGUAGE: English  
AB . . . and adverse effects of cisapride in combination with  
macrolide antibacterials, azole antifungal agents, antidepressants,  
antiretrovirals, grapefruit juice, antileukotrienes, calcium antagonists,  
**H2 antagonists**, cardiac drugs, **antipsychotics**,  
and antibacterials, is presented.  
Tran Le

L17 ANSWER 5 OF 6 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN DUPLICATE 1

ACCESSION NUMBER: 93344779 EMBASE  
DOCUMENT NUMBER: 1993344779  
TITLE: Famotidine adjunctive pharmacotherapy for schizophrenia:  
Preliminary data.

AUTHOR: Deutsch S.I.; Rosse R.B.; Kendrick K.A.; Fay-McCarthy M.;  
Collins Jr. J.P.; Wyatt R.J.  
CORPORATE SOURCE: Dept. of Veterans Affairs Med. Ctr., Psychiatry Service,  
50  
SOURCE: Irving Street, N.W., Washington, DC 20422, United States  
Clinical Neuropharmacology, (1993) 16/6 (518-524).  
ISSN: 0362-5664 CODEN: CLNEDB  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 030 Pharmacology  
032 Psychiatry  
037 Drug Literature Index  
LANGUAGE: English  
SUMMARY LANGUAGE: English

AB The usefulness of the histamine-2 (H2) **antagonist**  
famotidine as an adjunct to conventional **antipsychotic**  
treatments of idiopathic psychotic disorders (i.e., schizophrenia and  
schizoaffective disorder) was investigated in an open-label study. After  
stabilization for at. . .

L17 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:207660 CAPLUS  
DOCUMENT NUMBER: 116:207660  
TITLE: Pharmacological comparison of the sigma recognition  
site labelled by [3H]haloperidol in human and rat  
cerebellum  
AUTHOR(S): Barnes, J. M.; Barnes, N. M.; Barber, P. C.;  
Champaneria, S.; Costall, B.; Hornsby, C. D.;  
Ironsides, J. W.; Naylor, R. J.  
CORPORATE SOURCE: Med. Sch., Univ. Birmingham, Birmingham, B15 2TT, UK  
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology  
(1992),

345(2), 197-202

CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 50-02-2, Dexamethasone 50-22-6, Corticosterone 50-23-7,

Hydrocortisone

50-52-2, Thioridazine 50-60-2, Phentolamine 51-55-8, Atropine,  
biological studies 52-39-1, Aldosterone 56-12-2, GABA, biological  
studies 56-40-6, Glycine, biological studies 57-83-0, Progesterone,  
biological studies 58-22-0, Testosterone 58-25-3, Chlordiazepoxide  
58-39-9, Perphenazine 59-33-6, Mepyrmine 60-26-4, Hexamethonium  
69-23-8, Fluphenazine 77-10-1, PCP 86-01-1 97-39-2, DTG 359-83-1,  
(+)-Pentazocine 361-37-5, Methysergide 465-65-6, Naloxone  
525-66-6, Propranolol 749-02-0, Spiperone 2062-78-4, Pimozide  
5786-21-0, Clozapine 7313-86-2, (-)Cyclazocine 7313-87-3

14198-28-8,

(-)SKF10,047 15676-16-1, Sulpiride 21500-98-1, TCP 34273-04-6  
51152-91-1, (-)-Butaclamol 56245-67-1, (+)-Butaclamol 58640-82-7,  
(+)SKF10,047 **66357-35-5**, Ranitidine 75859-04-0, Rimcazole  
85976-54-1 87134-87-0, Sch 23390 maleate 90182-92-6, Zacopride  
95417-67-7, L 687384

RL: BIOL (Biological study)

(binding of, to sigma recognition sites of human and rat cerebellum  
membranes, **antipsychotic** activity and pathol. of psychosis in  
relation to)